Induction of human fetal hemoglobin expression by adenosine-2’,3’-dialdehyde by Yinghong He et al.
He et al. Journal of Translational Medicine 2013, 11:14
http://www.translational-medicine.com/content/11/1/14RESEARCH Open AccessInduction of human fetal hemoglobin expression
by adenosine-2’,3’-dialdehyde
Yinghong He1,3†, Gerhard Rank2†, Miaomiao Zhang1, Junyi Ju1, Ronghua Liu1, Zhen Xu1, Fiona Brown2,
Loretta Cerruti2, Chi Ma1, Renxiang Tan1, Stephen M Jane2* and Quan Zhao1*Abstract
Background: Pharmacologic reactivation of fetal hemoglobin expression is a promising strategy for treatment of
sickle cell disease and β-thalassemia. The objective of this study was to investigate the effect of the methyl
transferase inhibitor adenosine-2’,3’-dialdehyde (Adox) on induction of human fetal hemoglobin (HbF) in K562 cells
and human hematopoietic progenitor cells.
Methods: Expression levels of human fetal hemoglobin were assessed by northern blot analysis and Real-time PCR.
HbF and adult hemoglobin (HbA) content were analyzed using high-performance liquid chromatography (HPLC).
DNA methylation levels on human gamma-globin gene promoters were determined using Bisulfite sequence
analysis. Enrichment of histone marks on genes was assessed by chromosome immunoprecipitation (ChIP).
Results: Adox induced γ-globin gene expression in both K562 cells and in human bone marrow erythroid
progenitor cells through a mechanism potentially involving inhibition of protein arginine methyltransferase
5 (PRMT5).
Conclusions: The ability of methyl transferase inhibitors such as Adox to efficiently reactivate fetal hemoglobin
expression suggests that these agents may provide a means of reactivating fetal globin expression as a therapeutic
option for treating sickle cell disease and β-thalassemia.
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Human globin genes undergo two switches during develop-
ment, from embryonic (ε) to fetal (γ) and from fetal (γ) to
adult (β) globin [1]. Reactivation of fetal hemoglobin (HbF)
in adults is one of the most effective strategies for treatment
of sickle cell disease and β-thalassemia as increased fetal
globin levels are associated with improved symptoms in
hemoglobinopathy patients [2].
To date, compounds such as 5-aza-2-deoxycytidine
(decitabine) [3], hydroxyurea (HU) [4], short-chain fatty
acids (SCFAs) [5], and histone deacetylase (HDAC) inhibi-
tors [6], have been used to increase HbF, although their* Correspondence: stephen.jane@monash.edu; qzhao@nju.edu.cn
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reproduction in any medium, provided the oreffects are variable. However, the mechanism of action is
not clear and remains controversial [2].
In previous studies, we determined that protein arginine
methyltransferase 5 (PRMT5) coupled with Dnmt3a and
related complexes played a critical role in human fetal glo-
bin gene repression [7,8]. In this report, we have found that
treatment with adenosine-2’,3’-dialdehyde (Adox), a methyl-
transferase inhibitor [9,10], can induce fetal hemoglobin
gene transcription in adult human bone marrow erythroid
progenitor cells. This activity of Adox may be associated
with inhibition of PRMT5.Methods
Cell culture and reagents
K562 cells were cultured as described previously [7]. To
generate human bone marrow (BM) erythroid progenitor
cells, isolated CD34+ cells were grown in StemSpan SFEM
medium with 1X CC100 cytokine mix for 6 days, then
reseeded into the same medium supplemented with SCFThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(2 μM), and β-estradiol (1 μM), and cultured for two more
weeks [11]. Cell surface marker analysis with CD71 and
Glycophorin A indicated that the cultured cells were
greater than 90% erythroid lineage. Human BM cells were
collected under approval by the Melbourne Health
Human Research Ethics Committee.
A 25 mM stock solution of adenosine-2’,3’-dialdehyde
(Adox, Sigma) was prepared in 0.04 M HCl. Decitabine
(Sigma) was prepared in phosphate-buffered saline (PBS).
Working solutions of both reagents were prepared by
dilution in PBS immediately prior to use.
Benzidine staining, Northern Blot, and DNA
methylation analysis
K562 cells were treated with Adox (2.5 μM) for 2 days
and washed twice with ice-cold phosphate-buffered saline.
The cell pellets were then resuspended in ice-cold phos-
phate-buffered saline. Benzidine solution (0.1% 3,3’-diami-
nobenzidine containing hydrogen peroxide) was added at
room temperature. Benzidine-positive cells were spun
onto a glass plate, examined by light microscopy and
photographed. Northern blot analysis of K562 cells was
performed as described previously [12]. Bisulfite sequence
analysis was performed as described previously [7]. PCR
was performed with HiFi Taq polymerase (Roche) as
follows: 30 cycles, 94°C for 20 s, 55°C for 20 s, and 68°C
for 35 s. PCR products were cloned into pCRII (Invitro-
gen) followed by nucleotide sequencing using the Big-
Dye Termination method (ABI). At lease 40 clones
were sequenced for each CpG site.
ChIP analysis
ChIP assays were performed as described previously [7].
H4R3me2s and histone H4 acetylation antibodies were pur-
chased from Abcam. Each experiment was performed inde-
pendently at least twice. The ChIP samples were analyzed
by quantitative real-time PCR using FastStart Universal
SYBR Green Master (Roche). A standard curve was pre-
pared for the primers using serial titration of the input
DNA. The percentage of ChIP DNA was calculated relative
to the input DNA from primer-specific standard curves
using Rotor-Gene 6000 Series Software 1.7.
Quantitative RT-PCR (Q-RT-PCR)
Total RNA was isolated from cells with Trizol reagent
(Invitrogen). cDNA was generated using a reverse tran-
scription system (Promega). The identities of the ampli-
fied bands were confirmed by sequencing. The PCR
conditions and primers were described previously [7],
and all samples were run in triplicate.
For bone marrow samples, plasmid DNA encoding
γ-globin, β-globin or α-globin was used to generate
the standard curve for determination of copy number.The number of molecules per nanogram total RNA from
bone marrow cells was calculated from standard curves
using Rotor-Gene 6000 Series Software 1.7.
HPLC for adult and fetal hemoglobin
Aliquots of one million cells were washed in phosphate-
buffered saline. The pellets were lysed by repeated freeze-
thaw. The supernatant was analyzed for HbF and adult
hemoglobin (HbA) content by ion-exchange high-perfor-
mance liquid chromatography (HPLC) using a Bio-Rad
VARIANT β-thalassemia Short Program.
Results and discussion
In order to test the effect of Adox to induce γ-globin,
K562 cells were treated and showed a dose response ef-
fect on activation (Figure 1A). Next, we performed a
time-course analysis of γ-globin induction by Adox. We
found that from day 2 γ-globin expression was readily
detected, but after day 6, induction stopped (Figure 1B).
This result suggested that Adox could induce γ-globin
very quick and it could also be metabolized during cell
proliferation. Adox also induced a dose-dependent in-
hibition of in vitro proliferation of K562 cells,similar to
the effect of decitabine (Figure 1C) [13]. Benzidine stain-
ing of K562 cells also showed activation effect of Adox
on γ-globin (Figure 1D). Q-RT-PCR analysis further con-
firmed a 9-fold induction of γ-globin gene expression by
Adox compared to the control (Figure 1E).
In keeping with previous results, the levels of histone
mark H4R3me2s on the γ-globin promoter triggered by
PRMT5 were significantly reduced in Adox-treated cells
compared to untreated cells (Figure 2A). PRMT5 inhibition
by Adox treatment followed a dose response (Figure 2B)
that occurred over the same drug concentration range as
γ-globin induction (Figure 1A).
DNA methylation has been shown to be important in
regulation of globin gene expression. Because Adox can
inhibit both DNA methylation and protein methylation in-
cluding histone tail methylation, we performed bisulfite
DNA sequencing experiments on globin genes. Using deci-
tabine as a positive control, we found that Adox signifi-
cantly reduced DNA methylation (Figure 2C). Together
these results suggested that Adox was a potent inducer of
γ-globin expression in K562 cells.
Next, in order to probe the effect of Adox on human
primary erythroid cells, we isolated human bone marrow
CD34+ cells and cultured them under optimal conditions
for erythroid cell differentiation [11]. We treated human
bone marrow cells (BM) with Adox and decitabine (both
refreshed twice a week). Total RNA from these cells was
isolated and analyzed by Q-RT-PCR. Adox treatment pro-
duced a dose–response effect on γ-globin gene expression
(Figure 3A). We also confirmed the effect of decitabine on
induction of γ-globin gene expression (Figure 3A). We
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Figure 1 Adox induced γ-globin gene expression in K562 cells. (A) Northern blot analysis of total RNA from K562 cells treated with indicated
concentrations of Adox for 2 days. (B) Northern blot analysis of total RNA from K562 cells treated with Adox (2.5 μM) for the indicated number of
days. (C) Effects of Adox on in vitro growth of K562 cells. K562 cells were treated with the indicated concentrations of Adox or PBS control (Ctrl)
and cell number/ml was determined at the indicated time. (D) Benzidine staining of K562 cells treated with Adox (2.5 μM) or PBS control (Ctrl) for
2 days. (E) Q-RT-PCR quantification of γ-globin from K562 cells treated with PBS control (Ctrl), Adox (2.5 μM) for 2 days, or decitabine (Deci, 4 μM)
for one week (refreshed once after 3 days treatment). Graphs show mean ± SD, n = 3.























































Figure 2 Modulation of DNA methylation and histone methylation by Adox in K562 cells. (A) Histone H4R3me2s ChIP analysis of γ-globin
promoter from K562 cells treated with Adox or PBS control. Graphs show mean ± SD, n = 3. (B) Western blot analysis of proteins with histone
H4R3me2s and anti-tubulin antibodies from K562 cells treated with indicated concentrations of Adox for 2 days. (C) Quantification of DNA
methylation at the human γ-globin gene in K562 cells treated with Adox, decitabine (Deci), or PBS control as in Figure 1E. Numbers on the
bottom represent the positions of the CpG dinucleotides relative to the transcriptional start site of the γ-globin gene. Ave indicates the average
methylation of the 4 total CpGs. **P < 0.01, Chi-squared test.
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induced 4-fold relative to the control. No morphological
differences of cells were observed during differentiation of
Adox treated cells, suggesting that Adox may not perturb
overall erythroid differentiation process (Figure 3B). Using
HPLC analysis, we confirmed that in human adult bone
marrow cells, Adox reactivated HbF to 8.6%, which was
2.7-fold relative to the control, whereas decitabine reacti-
vated HbF to 5.1%, which was 1.6-fold relative to the con-
trol (Figure 3C). The α-globin and β-globin of BM cellsshowed no induction in the presence of either Adox or
decitabine (Figure 3D, 3E&3F). Consistent with these
results, by ChIP analysis the levels of histone mark
H4R3me2s on the γ-globin promoter were greatly reduced
in Adox-treated or decitabine-treated BM cells compared
to control-treated cells (Figure 4A), but not on CDH1
promoter [14], indicating specificity of Adox for γ-globin
gene (Figure 4B). In keeping with this, histone H4 acetyl-
ation on the γ-globin promoter was also markedly





















































































Figure 3 The effects of Adox to induce fetal globin gene expression in human bone marrow erythroid progenitor cells. (A) Q-RT-PCR
quantification of γ-globin from human BM treated with indicated concentrations of Adox or decitabine (Deci, 4 μM) with refreshment twice a week
compared to PBS control (Ctrl) after 21 days of culture. Graphs show mean ± SD, n = 3. (B) Wright-Giemsa-stained adult bone marrow erythroid
progenitor cells at day 21 of differentiation. (C) HPLC analysis of globin in human BM cells treated with Adox (20 μM) or decitabine (4 μM). Peaks for
HbF are indicated. Data are representative of three independent experiments. (D) Q-RT-PCR quantification of mRNA levels of β-globin as percentage of
(β-globin + γ-globin) from human BM treated with Adox (20 μM) or decitabine (Deci, 4 μM) with refreshment twice a week compared to PBS control
(Ctrl) after 21 days of culture. Graphs show mean ± SD, n = 3. (E) Q-RT-PCR quantification of mRNA levels of β-globin as percentage of (β-globin + γ-
globin) from human BM treated with Adox (20 μM) or decitabine (Deci, 4 μM) with refreshment twice a week compared to PBS control (Ctrl) after 21
days of culture. Graphs show mean ± SD, n = 3. (F) Q-RT-PCR quantification of α-globin and β-globin from BM treated with Adox (20 μM) with
refreshment twice a week compared to PBS control (Ctrl) after 21 days of culture. Graphs show mean ± SD, n = 3.
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γ-globin gene in these BM cells was also reduced, but not
as significantly as in Adox-treated K562 cells (Figure 2C &
4D). These results suggested that inhibition of histone
methylation (H4R3me2s) might be more important than
reduction of DNA methylation for inducing fetal globin
expression in human bone marrow cells.Adox is an odorless methyltransferase inhibitor that
functions through a feedback loop [15]. Adox can inhibit
adenosylhomocysteine hydrolase activity thereby indir-
ectly inhibiting methyltransferases that catalyze adeno-
sylmethionine to adenosylhomocysteine [15]. Mice can
tolerate Adox at 100 μmol/kg without any ill-effect
























































































Figure 4 Modulation of DNA methylation and histone
methylation by Adox in human adult erythroid progenitor
cells. (A) Histone H4R3me2s ChIP analysis of γ-gene promoter from
human BM cells treated with either PBS control, Adox or decitabine as in
Figure 3C. Graphs show mean ± SD, n = 3. (B) Histone H4R3me2s ChIP
analysis of CDH1 promoter from human BM cells treated with either PBS
control or Adox as in Figure 3C. Graphs show mean ± SD, n = 3. (C)
Histone H4 acetylation ChIP analysis of γ-promoter from human BM cells
treated with either PBS control or Adox as in Figure 3C. Graphs show
mean ± SD, n = 3. (D) Quantitation of DNA methylation at the human γ-
globin gene in human BM cells treated as in (A). The numbers on the
bottom represent the positions of the CpG dinucleotides relative to the
transcriptional start site of the γ-gene. Ave indicates average methylation
of the 4 total CpGs. *P < 0.05, #P > 0.05 using Chi-squared test.
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of both DNA methylation and protein methylation. It is
unclear how this compares to decitabine because we
currently do not know the exact mechanism by which
decitabine induces γ-globin expression [18].
DNA methylation plays a critical role in modulation of
globin gene expression. Inhibitors of DNA methylation
or histone deacetylation, such as decitabine and butyrate,
have been shown to induce HbF [19,20]. Compared to
treatment of K562 cells, treatment of human BM cells
with Adox triggered less reduction in methylation at the
γ-globin gene, although there was more significant
demethylation beyond the transcription initiation site
(TIS) at CpG −53 and −50 (Figure 4D). This is similar to
results obtained by 5-Azacytidine treatment [18]. The fact
that immortalized K562 cells resemble embryonic eryth-
roid progenitors without expression of adult hemoglobin
may contribute to this difference. Also, hypermethylation
of the γ-globin promoter in BM cells may result in diffe-
rent requirements of Adox concentrations for inducing
γ-globin expression in K562 and BM cells. Nevertheless,
in this context, DNA hypomethylation produced by Adox
treatment may not be a major event or direct trigger in
the reactivation of γ-globin expression in human BM cells.
Histone modification or repressor complex (e.g. NURD
complex) reconstitution which might trigger histone
modification changes may contribute to the γ-globin gene
reactivation [21-23]. Alternatively, we cannot exclude the
possibility that different erythroid specific transcription
factors play roles upon γ-globin induction by Adox
treatment [24,25].
Histone methylation at H3K9, H3K27, H4K20, or sym-
metric methylation at H4R3 is normally associated with
repression of transcription [26,27]. We have previously
demonstrated that histone H4R3me2s is an early histone
mark induced by PRMT5 that can coordinately induce
other histone methylation events such as H4K20me3,
H3K9me3, H3K27me3, and deacetylation of histones [8].
In the current results, in human bone marrow cells, Adox
induced γ-globin expression independent of significant
hypomethylation of the gene. This suggests that histone
methylation, such as H4R3me2s, may play a more critical
role in regulation of globin genes.Conclusions
Our current studies indicat that Adox reactivates fetal
hemoglobin expression efficiently. We speculate that re-
activation of fetal globin by Adox may be through a
mechanism involving inhibition of PRMT5 in both K562
and human bone marrow erythroid progenitor cells.
These findings may contribute to the development of
new reagents for reactivating fetal globin expression as a
treatment for sickle cell disease and β-thalassemia.
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